25 completed, 11 unknown, 5 terminated, 2 withdrawn. 25 Phase 4, 9 Phase 3, 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 25 | Completed 12, Unknown 9, Terminated 2, Withdrawn 2 |
| Phase 3 | 9 | Completed 5, Terminated 3, Unknown 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow adefovir: new trials by email Literature Review of adefovir trials Research Report on adefovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide Vadadustat, Furosemide, Adefovir - Drug Interaction Potentiation | Phase 1 | Completed | Akebia Therapeutics | 62 | 2018-07-20 | 2019-03-22 |
| The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC Peginterferon Alfa-2A, Adefovir, entecavir,tenofovir, either of them - Hepatitis B | Phase 4 | Unknown | Shanghai Nanhui Nanhua Hospital | 150 | 2017-03-10 | 2017-05-03 |
| Drug Transporter Interaction Study PHENTRA_2015_KPUK pitavastatin, Metformin, digoxin - Healthy | Phase 4 | Completed | University of Cologne | 24 | 2016-04-01 | 2019-09-10 |
| Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Lamivudine, Adefovir, Entecavir - Hepatitis B, Chronic | Phase 4 | Unknown | Asan Medical Center | 90 | 2015-05-01 | 2015-12-30 |
| An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients Peginterferon alfa-2a plus Entecavir, Peginterferon alfa-2a plus Lamivudine, Peginterferon alfa-2a plus Adefovir - Chronic Hepatitis B | Phase 4 | Unknown | Ruijin Hospital | 324 | 2015-05-01 | 2015-09-25 |
| Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly, Nucleos(t)ide analogue therapy - Chronic Hepatitis B | Phase 4 | Completed | Seng Gee Lim | 254 | 2014-01-01 | 2019-09-24 |
| Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B PEG-Tα1, Placebo to match PEG-Tα1, Adefovir - Hepatitis B, Chronic | Phase 3 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 463 | 2013-08-01 | 2015-02-19 |
| Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Entecavir, Adefovir - Chronic Hepatitis B, Inadequate Response | Phase 4 | Unknown | Nanfang Hospital, Southern Medical University | 360 | 2013-03-01 | 2014-06-19 |
| 3E Extension Study oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks - Chronic Hepatitis B | Phase 4 | Unknown | Nanfang Hospital, Southern Medical University | 600 | 2013-03-01 | 2014-06-19 |
| Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Telbivudine, Enecavir, Adefovir - HBV-related Liver Cirrhosis | Phase 4 | Unknown | Lin Bingliang | 300 | 2013-02-01 | 2013-02-26 |
| TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA Lamivudine plus adefovir, Tenofovir - Chronic Hepatitis B | Phase 4 | Completed | Keimyung University Dongsan Medical Center | 171 | 2012-11-01 | 2016-10-28 |
| Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Tenofovir disoproxil fumarate, Lamivudine plus adefovir - Chronic Hepatitis B | Phase 4 | Unknown | Taipei Veterans General Hospital, Taiwan | 160 | 2012-09-01 | 2016-04-01 |
| PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients Peginterferon alfa-2a, Nucleos(t)ide analogue - Chronic Hepatitis B | Phase 4 | Completed | Foundation for Liver Research | 90 | 2012-05-25 | 2019-11-08 |
| Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study telbivudine plus adefovir, lamivudine plus adefovir - Chronic Hepatitis B | Phase 4 | Unknown | Korea University | 60 | 2011-05-01 | 2013-03-05 |
| Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B PEG-Tα1, Placebo to match PEG-Tα1, Adefovir - Hepatitis B, Chronic | Phase 2 | Completed | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 116 | 2011-05-01 | 2015-02-19 |
| Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Entecavir, Entecavir, Adefovir - Hepatitis B | Phase 4 | Unknown | Nanfang Hospital, Southern Medical University | 360 | 2010-12-01 | 2013-10-30 |
| A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC clevudine, Adefovir - Hepatitis B Associated Hepatocellular Carcinoma | Phase 4 | Completed | Bukwang Pharmaceutical | 33 | 2010-06-01 | 2014-12-18 |
| A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B Adefovir, Entecavir, Placebo - Hepatitis B, Chronic | Phase 4 | Completed | Hoffmann-La Roche | 280 | 2010-05-07 | 2017-04-10 |
| A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive Adefovir, peginterferon alfa-2a [PEGASYS] - Hepatitis B, Chronic | Phase 4 | Completed | Hoffmann-La Roche | 265 | 2010-04-01 | 2016-11-02 |
| An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B Clevudine 30mg, Clevudine 20mg+Adefovir dipivoxil 10mg, Clevudine 20mg - Chronic Hepatitis B | Phase 4 | Completed | Bukwang Pharmaceutical | 60 | 2010-03-01 | 2014-12-18 |
Showing 20 of 43. Sign in to see all of them.
Hepatitis B, Chronic (30) · Hepatitis B (11) · HIV Infections (3) · Acquired Immunodeficiency Syndrome (2) · Hepatitis, Chronic (2) · AIDS-Related Complex (1) · Ascites (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Hepatocellular (1) · Chronic Disease (1) · Fibrosis (1) · Hepatitis (1) · Liver Cirrhosis (1) · Patient Compliance (1)
Bristol-Myers Squibb (6) · Nanfang Hospital, Southern Medical University (4) · Bukwang Pharmaceutical (3) · Asan Medical Center (2) · Gilead Sciences (2) · Hoffmann-La Roche (2) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Korea University (2) · Novartis Pharmaceuticals (2) · Pharmasset (2) · Akebia Therapeutics (1) · Eisai Co., Ltd. (1) · Foundation for Liver Research (1) · Genexine, Inc. (1) · GlaxoSmithKline (1)
China (13) · South Korea (11) · United States (10) · Canada (7) · Taiwan (7) · Thailand (5) · Greece (4) · Singapore (4) · Australia (3) · Brazil (3) · Hong Kong (3) · Indonesia (3) · Philippines (3) · Poland (3) · Spain (3)
JinLin Hou, MD (2) · Byoung Kuk Jang, M.D (1) · Chenbo Hu (1) · Ghany Mark, MD (1) · Guoping Yang (1) · Hyung Joon Yim, M.D (1) · Jinlin Hou, MD (1) · June Sung Lee, M.D. (1) · Lin Bingliang, PhD (1)
PMID 17239478, PMID 17935165, PMID 22449251, PMID 23650172, PMID 27238752, PMID 27650283, PMID 29329305, PMID 31247117, PMID 32719417, PMID 33500704, PMID 33895361, PMID 38641023